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Background: Late gadolinium enhancement (LGE) cardiovascular magnetic resonance (CMR) enables state-of-the
-art in vivo evaluations of myocardial fibrosis. Although LGE patterns have been well described in asymmetrical
septal hypertrophy, conflicting results have been reported regarding the characteristics of LGE in apical
hypertrophic cardiomyopathy (ApHCM). This study was undertaken to determine 1) the frequency and distribution
of LGE and 2) its prognostic implication in ApHCM.
Methods: Forty patients with asymptomatic or minimally symptomatic pure ApHCM (age, 60.2 ± 10.4 years,
31 men) were prospectively enrolled. LGE images were acquired using the inversion recovery segmented
spoiled-gradient echo and phase-sensitive inversion recovery sequence, and analyzed using a 17-segment model.
Summing the planimetered LGE areas in all short axis slices yielded the total volume of late enhancement,
which was subsequently presented as a proportion of total LV myocardium (% LGE).
Results: Mean maximal apical wall thickness was 17.9±2.3mm, and mean left ventricular (LV) ejection fraction was
67.7 ± 8.0%. All but one patient presented with electrocardiographic negative T wave inversion in anterolateral
leads, with a mean maximum negative T wave of 7.2 ± 4.7mm. Nine patients (22.5%) had giant negative T waves,
defined as the amplitude of ≥10mm, in electrocardiogram. LGE was detected in 130 segments of 30 patients
(75.0%), occupying 4.9 ± 5.5% of LV myocardium. LGE was mainly detected at the junction between left and right
ventricles in 12 (30%) and at the apex in 28 (70%), although LGE-positive areas were widely distributed, and not
limited to the apex. Focal LGE at the non-hypertrophic LV segments was found in some ApHCM patients, even
without LGE of hypertrophied apical segments. Over the 2-year follow-up, there was no one achieving the study
end-point, defined as all-cause death, sudden cardiac death and hospitalization for heart failure.
Conclusions: LGE was frequently observed not only in the thickened apex of the heart but also in other LV
segments, irrespective of the presence or absence of hypertrophy. The simple presence of LGE on CMR was not
representative of adverse prognosis in this population.
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Apical hypertrophic cardiomyopathy (ApHCM) is a
unique phenotype of hypertrophic cardiomyopathy
(HCM) with a pathologic hypertrophy of the left ventricu-
lar (LV) apex and an “ace-of-spade” configuration of the
LV cavity at end-diastole by echocardiography or cardio-
vascular magnetic resonance (CMR). Despite a relatively
favorable prognosis for ApHCM, severe clinical manifesta-
tions including arrhythmias and life-threatening apical
aneurysm have been occasionally reported [1]. Although
transthoracic echocardiography has been traditionally
used for diagnosing HCM, the diagnosis of ApHCM by
echocardiography is sometimes challenging. In this special
setting, CMR can provide additional, more accurate infor-
mation on LV morphology [2]. In addition, the recent
introduction of late gadolinium enhancement (LGE) CMR
allows the accurate detection of myocardial fibrosis in an
in vivo setting [3]. According to several earlier literatures,
LGE is frequently observed in asymmetrical septal HCM
patients, and is also closely associated with severe hyper-
trophy and a high risk of sudden cardiac death [3–6].
However, LGE features of CMR in ApHCM have rarely
been reported, and moreover results disagree regarding
LGE patterns in ApHCM [4,7,8]. Therefore, this study was
set out to determine the frequency and distribution of
LGE on contrast-enhanced CMR in ApHCM. In addition,
based on close follow-up conducted over 2 years, we
sought to determine whether LGE on CMR has prognos-
tic impact in this population.
Method
Study population
In this prospective study, we enrolled 40 asymptomatic
or minimally symptomatic ApHCM patients (31 men;
average age 60.2 ± 10.4 years) scheduled for CMR in our
institution. Diagnosis of ApHCM was established based
on the demonstration of asymmetrical LV hypertrophy
confined to the LV apex, an apical wall thickness≥ 15
mm, and a maximum apical thickness to maximum
basal thickness ratio of ≥ 1.3 by CMR. Great care was
taken to enroll ApHCM patients with involvement of
the apex only [9,10]. All patients were evaluated with in-
vasive or computed tomographic coronary angiography
for the presence of coronary artery disease, and patients
with significant stenosis, defined as luminal stenosis of
> 50%, were systematically excluded. Patients who were
not in sinus rhythm were excluded, as well. The study
protocol was approved by the institutional review board
of our hospital and informed consent was obtained from
all participants before enrollment.
Electrocardiography
A “giant” negative T wave in electrocardiogram (ECG)
was defined as a voltage of negative T wave of ≥ 1 mV(≥10 mm) in any anterior lead. Maximum T wave inver-
sion from leads V3, V4, V5, and V6 and summed T wave
amplitudes in these leads were compared.
Echocardiography
All echocardiographic examinations were performed on
the same day as CMR using a commercially available
machine (Vivid 7, GE, Horten, Norway) with subjects in
the left lateral decubitus position. A routine standard
echocardiographic examination, which included mea-
surements of LV systolic and diastolic functions, was
performed. In each case, maximal apical wall thickness
at end-diastole was determined using the standard apical
four-, two-, and three-chamber views.
CMR protocol
CMR was performed using a 1.5T scanner (Sonata Mag-
netom, Siemens, Erlangen, Germany). Steady-state free
precession cine images were used to quantify LV func-
tion (slice thickness of 6 mm), and LV short-axis images
were acquired from apex to base to cover entire LV
volumes. Repeated breath-holds were required in order
to create adequate images. The temporal resolution was
25–30 frames per RR interval. LV mass was measured
with commercially available software (QMASS MR;
Medis, Leiden, Netherlands) by a single experienced ob-
server unaware of echocardiographic data. LGE images
were acquired 10 minutes after the intravenous adminis-
tration of gadopentetatedimeglumine (0.15 mmol/kg
intravenous injection, Magnevist; Schering, Berlin, Ger-
many), and followed by a flush of 20mL of saline at the
same rate. LGE images from long-axial, short-axial, and
4-chamber views were acquired using the inversion re-
covery segmented spoiled-gradient echo and phase-
sensitive inversion recovery methods. LGE images were
evaluated using a 17-segment model, as suggested by the
American Heart Association criteria [11]. LV was evalu-
ated in the short-axis images of basal, mid, and apical
segments. Basal and mid cavities were divided into 6
equal segments: anterior, anteroseptal, inferoseptal, in-
ferior, inferolateral, and anterolateral. Apical segments
were divided into 4 segments: anterior, septal, inferior,
and lateral. Apical cap constituted the 17th segment of
LV myocardium.
Data analysis
Imaging data were analyzed with a commercially avail-
able postprocessing workstation (cmr42, Circle Cardio-
vascular Imaging Inc., Calgary, Canada). Endocardial and
epicardial contours were traced manually on short-axis
cine MR images of the LV at end diastole and end sys-
tole to assess end-diastolic and end-systolic volumes, LV
ejection fraction, and LV mass. In order to assess the
presence or absence of LGE and its extent, all short-axis
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identify areas of normal (completely nulled) myocar-
dium. LGE was considered present when the signal in-
tensity of the index myocardial segment was greater
than 6SD, as compared with the remote normal myo-
cardial signal [12,13]. Summing the planimetered areas
of LGE in all short-axis slices yielded total volume of
delayed enhancement, which was subsequently
expressed as a proportion of total LV myocardium (%
LGE). Contrast-enhanced images were analyzed by two
experienced observers unaware of other CMR, echo-
cardiographic, and clinical data (K.H.K., I.C.H.). Any
discrepancy in analysis between the 2 readers was
resolved by a senior observer (W.L.). Additionally, LGE
in each of the 17 segments was graded using a 2-point
scale (segmental fibrosis score; 0 = absence of LGE,
1 = presence of LGE), if CMR LGE was present using
the 6SD method. Figures 1 and 2 are representative
CMR examples of patients without and with diffuse
LGE, respectively.
Follow-up
In order to determine the impact of CMR-detected LGE
on prognosis, ApHCM patients were clinically followed
every 3 or 6 months for at least 2 years at a specialized
HCM clinic by one cardiologist (K.H.K.). No patient was
lost to follow-up. The study endpoint was a composite
of all-cause mortality, sudden cardiac death, and
hospitalization for heart failure.
Statistical analysis
Data are presented as mean ± SD for continuous vari-
ables and as numbers (%) for categorical variables, as
appropriate. After confirming the normality of the dis-
tributions of continuous variables using the Shapiro-
Wilk test, the unpaired Student t-test was used to
analyze normally distributed variables, and the Mann–
Whitney U test to analyze non-normally distributed
variables. Spearman correlation analysis was used to
explore the possibilities of correlations between LV
maximal wall thickness, ECG-determined T wave
amplitudes. All statistical analyses were performed
using statistical software package for windows (SPSS




Baseline clinical and demographic characteristics of the
40 ApHCM patients are illustrated in Table 1. Ages ran-
ged from 28 to 80 years (median, 5 9years). There were
31 men and 9 women. Of the 40 patients, 25 (63.5%)
were completely asymptomatic and 15 had only mild
symptoms (New York Heart Association class I or II) atthe time of study enrollment. The primary reason for
initial echocardiography in the 25 asymptomatic patients
was a general medical check-up or family screening.
Three patients (7.5%) had a history of unexplained syn-
cope. Although 17 patients (42.5%) had a history of trea-
ted hypertension, blood pressure had been well
controlled for> 2 years in all. One patient (2.5%) had a
family history of HCM and 3 patients (7.5%) had a fam-
ily history of sudden death. All but one patient presented
T wave inversion in anterolateral leads, with a mean
maximum negative T wave amplitude of 7.8 ± 4.2mm. Of
the 39 patients with T wave inversion on ECG, 12 (30%)
presented giant negative T waves.
Echocardiography
Echocardiographic variables are presented in Table 2. In
11 patients referred to our hospital, 2D echocardiogram
performed at a local clinic reported mildly increased ap-
ical wall thickness (≥ 12mm), but it did not reach 15mm
in most thickened apical segment even in the presence
of negative T wave inversion. Based on echocardiography
performed in our hospital, there was no patient who had
an LV outflow tract obstruction, either at rest or after
provocative valsalva maneuvers. Left atrial dimension
was slightly increased (44.2 ± 4.8mm), suggestive of
chronic LV diastolic dysfunction. Mean maximal apical
wall thickness was 16.7 ± 2.4 mm. There was no signifi-
cant correlation between maximal apical wall thickness
and the amplitude of T wave inversion (r = 0.15, p = 0.34)
or the sum of T wave amplitudes in precordial leads
(r = 0.15, p = 0.36).
CMR
In total, 680 segments were analyzed for LV wall thick-
ness and LGE on CMR. Mean LV mass index was
102.2 ± 28.9gm/m2 and LV ejection fraction was
67.7 ± 8.0% (Table 3). Maximal apical wall thickness ran-
ged from 15mm to 26mm (17.9±2.3mm), which was
significantly greater than that obtained by echocardiog-
raphy (p< 0.01). Contrast images demonstrated LGE
representing myocardial fibrosis in 30 (75.0%) of the 40
patients and in 130 (19%) of the 680 segments. Total
volume of LGE was estimated to be 9.7 ± 10mL, corre-
sponding to 4.9 ± 5.5% (rage 0.5% to 26%) of total LV
myocardium. The most frequently involved myocardial
segments were the apical cap (28 patients (70%)), fol-
lowed by the apicolateral segment (20 patients (52.5%)).
Of note, LGE was observed not only in the apex of the
heart but also in the other segments of the LV, espe-
cially in mid anterior and anterolateral segments of the
LV and at anterior and posterior attachment points of
the right ventricle to the interventricular septum. In
addition, LGE was detected in hypertrophied as well as
non-hypertrophied areas of the heart. LGE distribution
Figure 1 A representative example of ApHCM without late gadolinium enhancement (LGE) by CMR. (A) Long axis CMR cine images
clearly demonstrated the presence of apical hypertrophy. However, short (B) and long axis (C) CMR images showed no LGE. (D) Giant negative
T wave inversion in anterior leads of electrocardiogram was evident.
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transmural (≥75% of any segmental wall thickness) in
only 2 (7%) of the 30 patients, exclusively limited to the
apex and were nontrasmural in the other 28 (93%)
patients, in focal, multifocal or confluent patterns.
Interestingly, LGE observed at apical segments was in a“subendocardial” pattern (47 (48%) of 97 apical seg-
ments showing LGE), similar to LGE found in ischemic
cardiomyopathy. Representative CMR images of LGE
patterns are illustrated in Figure 4.
Although no significant correlation between the
depth of T wave inversion on ECG and maximal apical
Figure 2 A representative example of ApHCM with late gadolinium enhancement (LGE) by CMR. (A) Long axis CMR cine images clearly
demonstrated the presence of apical hypertrophy, as in Figure 1. In contrast, short (B) and long axis (C) CMR images showed diffuse LGE at the
basal and mid interventricular septum or RV insertion site (non-hypertrophic segment) and at the apex (hypertrophic segment), as indicated by
the arrow. (D) Negative T wave inversion in anterior leads of electrocardiogram was present.
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maximal apical wall thickness determined by CMR dis-
played a modest but significant correlation with the
amplitude of T wave inversion on ECG (r = 0.38,
p = 0.016). An apical aneurysm was detected in 5
patients (12.5%), and 3 of these (60%) were not
detected by routine echocardiography.Follow-up
Over the 2-year follow-up, there was no one who
achieved the study end-point, defined a priori, as all-
cause death, sudden cardiac death and hospitalization for
heart failure. Arrhythmic events that were assessed in 23
patients who underwent 24-hour Holter monitoring both
at baseline and follow-up were also unremarkable and
Table 1 Baseline clinical and electrocardiographic
characteristics of the study population
N=40
Men/Women 31/9
Age 60.2 ± 10.4
Body surface area (g/m2) 1.74 ± 0.17
Family history of HCM 1(2.5%)
Family history of SCD 3 (7.5%)
History of syncope 3 (7.5%)
NYHA functional class I/II 25 (63.5%)/15 (37.5%)
Hypertension 17 (42.5%)
Diabetes mellitus 4 (10%)
Smoker 3 (7.5%)
Medications
Calcium-channel blockers 13 (32.5%)




SBP/DBP 125.9 ± 13.7/75.9 ± 8.7
Electrocardiogram
T wave inversion 39 (97.5%)
Giant T waves ≥10mm 12 (30%)
HCM denotes hypertrophic cardiomyopathy; SCD, sudden cardiac death;
NYHA, New York Heart Association; ACEi/ARB, angiotension converting
esterase inhibitor/angiotensin receptor blocker; S(D)BP, systolic (diastolic)
blood pressure; ECG, electrocardiogram.
Table 3 CMR findings
LV end-diastolic volume (mL) 130.5 ± 26.3
LV end-diastolic volume index (mL/m2) 76.0 ± 13.9
LV end-systolic volume (mL) 43.9 ± 18.1
LV end-systolic volume index (mL/m2) 25.2 ± 9.1
LV ejection fraction (%) 67.7 ± 8.0
LV mass (gm) 178.0 ± 61.1
LV mass index (gm/m2) 102.2 ± 28.9
Maximal apical wall thickness at end-diastole (mm) 17.9 ± 2.3
LV denotes left ventricle.
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extent, either.
Discussion
Japanese investigators first reported ApHCM as a mor-
phologic variant of HCM characterized by a strikingTable 2 Echocardiographic variables
LV end-diastolic dimension (mm) 48.3 ± 7.2
LV end-systolic dimension (mm) 27.3 ± 4.8
LV ejection fraction (%) 67.7 ± 7.2
IVS thickness (mm) 10.3 ± 1.6
PW thickness (mm) 9.8 ± 1.3
Maximal apical wall thickness at end-diastole (mm) 16.7 ± 2.4
LA end-systolic dimension (mm) 44.2 ± 4.8
Peak E wave velocity (m/s) 0.58 ± 0.12
Peak A wave velocity (m/s) 0.54 ± 0.16
Early mitral annular velocity (E’, m/s) 0.11 ± 0.42
Mitral inflow/annular velocity ratio (E/E’) 12.96 ± 4.4
LV denotes left ventricle; IVS, interventricular septum; PW, posterior wall; and
LA, left atrium.electrocardiographic pattern of deep T wave inversion in
precordial leads and a distinctive angiographic “ace-of-
spades” like appearance of the LV at end-diastole [14-
16]. Subsequently, echocardiographically detected
ApHCM has been repeatedly reported at several centers
outside of Japan, although the characteristic electrocar-
diographic patterns are reported inconsistently in West-
ern patients [1,17]. In the present study, in accordance
with previous observations [1,18], all but 1 patient
(97.5%) presented with electrocardiographic alterations
of ventricular repolarization, in the form of T wave in-
version. The prevalence of a giant negative T wave in
our population is also similar to that reported in a Can-
adian study [1].
Two-dimensional echocardiography is now generally
regarded as the “clinical standard” noninvasive diagnos-
tic test for HCM [19,20]. However, conventional echo-
cardiography has its technical limitations. As shown in a
previous study, it tends to underestimate the magnitude
of hypertrophy in the anterolateral free wall, which is
frequently spatially away from the center of the echocar-
diographic sector in parasternal short axis view, resulting
in poor lateral resolution, and inconclusive delineation
of the epicardial border [21]. Another pitfall of conven-
tional echocardiography is that procurement of apical
wall images is not easy due to the close proximity of the
echocardiographic probe and the apex, which may result
in missing the diagnosis of ApHCM [22,23]. In a previ-
ous study, CMR was compared with echocardiography
in terms of its ability to detecting hypertrophied seg-
ments, and it was concluded that CMR is superior to
echocardiography, especially with respect to the detec-
tion of apical segmental hypertrophy [24]. In line with
findings of the previous study [24], we found that echo-
cardiography significantly underestimated apical wall
thickness, as compared with CMR (16.7 ± 2.4 mm vs.
17.9 ± 2.3 mm, p< 0.01). Furthermore, echocardiograms
performed at a local clinic did not demonstrate sufficient
LV apical wall thickness for objective evidence of diag-
nosing ApHCM in 11 out of 40 patients, that is, in these
patients apical wall thickness were< 15mm even in the
presence of electrocardiographic T wave inversion,
Figure 3 Distribution of LGE on CMR in ApHCM patients. In most patients, myocardial LGE was localized in the apicolateral and apical cap
segments (52.5%, 70.0% respectively).
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echocardiography in the accurate delineation of the epi-
cardial border. The advantage of CMR with respect to
the visualization of hypertrophied apical LV segments,
sometimes not readily identifiable by conventional echo-
cardiography, has been previously demonstrated inFigure 4 LGE patterns observed in ApHCM patients. (A) Subendocardia
Multifocal LGE at the RV insertion into the septum and mid anterior wall; (DApHCM [2]. The significant correlation found in the
present study between the amplitude of T wave inver-
sion on ECG and maximal apical wall thickness mea-
sured by CMR, but not by echocardiography, confirms
the advantage of CMR over echocardiography for the
assessments of apical pathology.l LGE with transmurality of ≥75%; (B) Fuzzy and confluent LGE; (C)
) Discrete (focal) pattern at mid myocardium.
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is not an uncommon finding in even asymptomatic or
mildly symptomatic ‘pure’ ApHCM patients. Further-
more, we observed that apical segments, including apical
cap, were the most frequently involved LGE sites in
ApHCM patients. However, we found that LGE was not
limited to hypertrophic apical segments, and that it was
also present in basal segments, at the anterior and pos-
terior junctions between the septum and RV free wall,
and additionally in non-hypertrophied segments of
ApHCM (Figure 3). More importantly, LGE observed at
apex (including apical cap) (47 (48%) of 97 apical seg-
ments showing LGE) was in a “subendocardial” pattern,
quite unlike the patchy or focal mid-wall LGE pattern
frequently observed in asymmetrical septal HCM
patients [4,5,8]. Given that “ischemic-type” LGE is usu-
ally characterized by subendocardial involvement with or
without extension into subepicardium [25], the subendo-
cardial LGE pattern at apex in our population strongly
suggests previous subendocardial ischemia. Since we ex-
clusively recruited ApHCM patients without significant
epicardial coronary artery disease, this “ischemic-type”
LGE should be attributable to mechanisms other than
epicardial coronary stenosis. A hypertrophied apical wall
with relatively deficient coronary blood flow may be a
plausible explanation for this “ischemic-type” LGE. How-
ever, an increment in intra-apical cavitary pressure that
might subsequently lead to suboptimal perfusion to the
subendocardial area could explain “ischemic-type” LGE
at the apex, as well [26].
Although few studies have addressed LGE in ApHCM,
spatial distributions of LGE in ApHCM disagree. In one
earlier report, LGE was described only at the apex with-
out any involvement of the base or mid ventricular levels
[7], whereas in another report LGE was observed widely
in ApHCM patients. More recently, Amano et al. showed
the presence of LGE at apex as well as mid-ventricular
segments in ApHCM patients [27]. However, they only
enrolled symptomatic patients, and thus we still have no
data regarding whether LGE is widely distributed even in
asymptomatic or minimally symptomatic ApHCM
patients. In fact, our study is the largest to investigate the
extent and distribution of LGE in an asymptomatic or
minimally symptomatic subset of ApHCM, and based on
our finding, LGE appears to be distributed across all
myocardial segments even in the asymptomatic or min-
imally symptomatic ApHCM population.
Although ApHCM patients enrolled in the current
study were carefully followed for at least 2 years, no one
achieved the study end-point (all-cause death, sudden
cardiac death or hospitalization for heart failure). No sig-
nificant arrhythmic events were found, either. Due to
the relatively short follow-up period, however, definite
conclusions cannot be drawn.Some limitations of this study warrant consideration.
First, the presence of LGE on contrast-enhanced CMR
has been well validated in animal models and in humans
with ischemic heart disease [28,29]. Although LGE on
CMR in HCM patients has been shown to represent
increased myocardial collagen in one HCM patient with
heart failure, extensive evaluation regarding validation of
LGE on CMR has not been systematically performed in
ApHCM patients, and thus, the view that LGE exclu-
sively reflects myocardial scarring is, more or less, specu-
lative. Second, the lack of long-term longitudinal follow-
up data prevented definite conclusion of prognostic im-
pact of LGE on CMR in this subset of ApHCM patients.
Same caution should be exercised with regard to the pre-
diction of arrhythmic events in this population.
Conclusions
LGE on CMR is not an uncommon finding in ApHCM
patients, and is widely distributed across almost all LV
myocardial segments, including non-hypertrophied seg-
ments. Given no morbidity or mortality during 2 years
of follow-up, it would appear that the simple presence of
LGE on CMR is unlikely to be representative of adverse
prognosis in this asymptomatic or minimally symptom-
atic ApHCM population, esp. in the short term.
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